Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133822 | 0.91 | GRM5 (0.41) | ADORA2AADORA1GABRA1GABRG2GABRB3 | |
| SCHEMBL6133677 | 0.87 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL6135151 | 0.87 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL6134581 | 0.87 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL6134826 | 0.86 | ADORA2A (0.39) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL6134659 | 0.86 | ADORA2A (0.39) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL6133772 | 0.85 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL6133450 | 0.84 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BADORA3HRH3 | |
| SCHEMBL6133969 | 0.83 | MGMT (0.41) | ADORA2AADORA1 | |
| SCHEMBL6133517 | 0.82 | ADORA2A (0.38) | ADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885GABRA1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.